The interleukin-2 receptor alpha chain (IL-2Rα, also called CD25) sits at a critical junction in immune regulation. When IL-2 binds to its receptor on T cells, it triggers proliferation of both effector T cells that drive immune responses and regulatory T cells (Tregs) that shut them down. The balance between these two arms determines whether your immune system attacks pathogens appropriately or turns on your own tissues. rs41295061 is a regulatory region variant¹¹ regulatory region variant
Located at chr10:6,072,697 GRCh38 in the IL2RA locus, affecting transcription factor binding rather than protein sequence in the IL2RA locus that influences this fundamental balance.

The Mechanism

A proteome-wide allele-specific binding screen²² proteome-wide allele-specific binding screen
Butter et al. PLoS Genetics 2012, PMID 23028375 found that the transcription factor LEF1 binds approximately 8 times more strongly to the minor A allele at rs41295061 than to the common C allele. LEF1 is a downstream effector of the Wnt signaling pathway that regulates T cell development and survival. This differential binding suggests the A and C alleles create functionally different regulatory environments for IL2RA transcription. Separately, a functional study³³ functional study
Qu et al. J Immunol 2009, PMID 19794070 showed that rs41295061 marks one major IL2RA susceptibility locus, while a nearby independent variant tagged by rs3118470 further reduces IL2RA expression through a distinct mechanism.

The net result of common C allele homozygosity is lower soluble IL-2RA levels in circulation. Fine-mapping of the IL2RA locus⁴⁴ Fine-mapping of the IL2RA locus
Lowe et al. Nature Genetics 2007, PMID 17676041 found that T1D-risk IL2RA genotypes produce significantly lower concentrations of circulating soluble IL-2RA (p=6.28×10⁻²⁸), a biomarker that reflects regulatory T cell activity. Reduced IL-2 signaling through the IL-2Rα high-affinity complex impairs Treg maintenance, tilting the immune balance toward autoimmunity.

The Evidence

The association of rs41295061 with type 1 diabetes is among the strongest non-HLA genetic signals for this disease. A meta-analysis of 10 independent studies⁵⁵ meta-analysis of 10 independent studies
Tang et al. J Cell Mol Med 2015, PMID 26249556 totaling 32,646 individuals identified rs41295061 as one of the three most associated IL2RA SNPs for T1D, alongside rs11594656 and rs2104286. The minor A allele showed a protective odds ratio of 0.67 (95% CI: 0.60–0.76), meaning the C allele homozygote is the T1D-risk genotype.

The same variant has opposing effects in Graves' disease (autoimmune hyperthyroidism). A study of 1,474 Graves' disease patients⁶⁶ study of 1,474 Graves' disease patients
Chistiakov et al. Scand J Immunol 2011, PMID 21815908 found that the A allele confers increased Graves' risk (OR 1.43, p=0.001), with A allele carriers showing elevated soluble IL-2RA levels in both patients and healthy controls. This allele-specific direction reversal across autoimmune diseases is biologically plausible: the same IL-2 signaling axis can drive pathogenic immune responses in different directions depending on which immune cell populations dominate in each disease.

Beyond T1D and Graves' disease, rs41295061 shows modest associations with juvenile idiopathic arthritis⁷⁷ juvenile idiopathic arthritis
Hinks et al. Arthritis Rheum 2009, PMID 19116909 (OR 0.80 for A allele, p=0.05) and ANCA-associated vasculitis⁸⁸ ANCA-associated vasculitis
Carr et al. BMC Med Genet 2009, PMID 19265545 (p=0.0122), though these associations are weaker than the T1D signal. The IL2RA locus appears to influence broad immune dysregulation rather than a single disease-specific pathway.

Practical Implications

The CC genotype (the most common globally, ~83% of Europeans by Hardy-Weinberg estimate) is the T1D risk genotype. However, it is important to emphasize that T1D is a polygenic, multifactorial disease — HLA genotype alone accounts for ~50% of genetic risk, and rs41295061 is a contributing factor, not a deterministic predictor. The vast majority of CC homozygotes will never develop T1D. Monitoring for early signs of autoimmune disease is the most actionable response to this genotype.

The heterozygous AC genotype confers intermediate T1D risk reduction, and the rare AA homozygote is associated with meaningfully lower T1D susceptibility but modestly elevated Graves' disease risk.

For individuals with a family history of T1D, Graves' disease, or other autoimmune conditions, knowing rs41295061 status adds context to a genetic risk picture that should also include HLA typing, PTPN22 rs2476601, and CTLA4 rs3087243. IL2RA variants like this one are particularly relevant for understanding the IL-2 pathway's role in immune homeostasis.

Interactions

rs41295061 operates in the same IL2RA locus as rs2104286, the other major IL2RA T1D variant already in this database. These two variants have partially overlapping but independent effects: rs2104286 is an intronic variant with its own effect on IL2RA expression, while rs41295061 operates through a distinct regulatory mechanism involving LEF1 binding. Conditional regression analyses show rs3118470, a separate variant near rs41295061, confers additional independent risk after accounting for rs41295061 (p=5×10⁻³).

The IL2RA locus interacts functionally with PTPN22 rs2476601 (the R620W T-cell activation variant) and CTLA4 rs3087243 (the immune checkpoint variant). Both of those variants impair T-cell negative regulation through different mechanisms: PTPN22 reduces TCR signaling threshold while CTLA4 reduces co-stimulatory braking. Combined, these three regulatory pathway variants likely compound autoimmune susceptibility, though their joint effect has not been formally quantified in a multi-SNP interaction model.

Ghrelin is the stomach's hunger signal — it rises before meals and drives appetite through the growth hormone secretagogue receptor (GHSR-1a)¹¹ growth hormone secretagogue receptor (GHSR-1a)
The only known peripherally derived orexigenic receptor in humans; signals through both homeostatic hypothalamic circuits and mesolimbic reward pathways. How much GHSR protein is available in the brain determines how strongly ghrelin can drive eating behavior. rs490683 sits in the GHSR gene promoter, roughly 9 kb upstream of the coding sequence, at a site where the transcription factor nuclear factor 1 (NF-1)²² nuclear factor 1 (NF-1)
NF-1 proteins are a family of transcriptional activators that bind to TTGGCN₅GCCAA consensus sequences; they regulate expression of numerous genes involved in tissue homeostasis and energy metabolism normally binds and activates transcription. The rs490683-G allele preserves this binding site (the NF-1 consensus motif GCCA is intact); the C allele converts it to CCCA, disrupting binding and reducing promoter activity.

The Mechanism

Gel-shift (electrophoretic mobility shift assay) experiments from Mager et al. 2008³³ Mager et al. 2008
Finnish Diabetes Prevention Study group; N=507 overweight adults with impaired glucose tolerance; 3-year lifestyle intervention demonstrated that nuclear proteins bind to the G-allele sequence with 745% higher affinity than to the C-allele sequence. Reporter assays in Matzko et al. 2012⁴⁴ Matzko et al. 2012
Bariatric surgery cohort at Geisinger Clinic; N>650 RYGB patients followed 30 months confirmed that the CC genotype (both alleles disrupting NF-1 binding) reduces GHSR promoter activity by approximately 20% compared to the GG genotype. The result is a measurable difference in ghrelin receptor density: GG individuals express more GHSR in appetite-regulating brain regions, making them more sensitive to circulating ghrelin and creating a stronger biological pull toward eating during energy restriction.

The Evidence

The Finnish Diabetes Prevention Study⁵⁵ Finnish Diabetes Prevention Study
507 overweight adults with impaired glucose tolerance randomized to intensive lifestyle intervention vs. control; 3-year follow-up; rs490683 was one of 7 GHSR variants genotyped found that rs490683-CC individuals showed the highest weight loss in the entire study population (p=0.032). The association extended to glucose metabolism: CC carriers maintained lower two-hour plasma glucose levels compared to CG heterozygotes (p=0.020) through the follow-up period. This functional SNP was the strongest GHSR variant in the study in terms of metabolic and weight outcomes.

Surgical validation came from a 650-patient RYGB cohort⁶⁶ 650-patient RYGB cohort
Roux-en-Y gastric bypass patients at Geisinger Health System; 30-month post-surgical follow-up; genotyped for 4 GHSR promoter variants where CC genotype again predicted the most weight loss post-operatively (additive model p=0.011, dominant model p<0.0097). The consistency across lifestyle intervention and bariatric surgery settings strengthens the causal interpretation.

The most recent and most direct test used a meal-replacement hypocaloric diet⁷⁷ meal-replacement hypocaloric diet
N=96 obese adults (BMI>35); normocaloric hyperproteic formula twice daily for 12 weeks; Spanish population: non-G-allele carriers (CC genotype) lost an average of 8.5 kg vs. only 2.6 kg in G-allele carriers (p=0.01), representing a 3.3-fold difference in weight loss response to the same dietary intervention. Fat mass loss (-7.7 vs -2.6 kg), waist circumference reduction (-7.2 vs -2.9 cm), fasting glucose change (-12.1 vs -3.1 mg/dL), and insulin reduction (-10.8 vs -3.9 IU/L) all followed the same pattern. G-allele carriers also consumed significantly more calories, carbohydrates, fats, and proteins during the dietary intervention period, consistent with elevated ghrelin receptor signaling overriding dietary restraint.

Practical Actions

For GG individuals (the majority of the population), higher baseline GHSR expression means that ghrelin signaling is stronger during caloric restriction — the biological pull toward eating is more powerful and more persistent than in CC carriers. This does not mean dietary interventions cannot work; it means they face a genuine biological headwind. Strategies that reduce ghrelin levels most effectively — high-protein meals, resistance training, adequate sleep — take on added importance. Monitoring weight response to dietary interventions and adjusting protocol when responses are modest helps GG individuals find what works rather than attributing poor results to personal failure.

For GC heterozygotes, one functional copy of the NF-1 site remains intact, producing an intermediate expression level and intermediate intervention response.

CC carriers represent the minority who derive the greatest benefit from dietary restriction programs and should expect above-average weight loss responses to structured interventions.

Interactions

rs490683 sits in the same GHSR promoter haplotype block as rs2922126 and rs9819506, which are also on the platform. Carriers of multiple GHSR promoter risk variants may experience compounding effects on ghrelin receptor expression beyond what any single variant predicts. The ghrelin ligand side of the system is covered by rs696217 (GHRL Leu72Met), which affects postprandial ghrelin suppression; individuals carrying both impaired ghrelin suppression (rs696217 T allele) and elevated ghrelin receptor expression (rs490683 GG) may face additive appetite dysregulation affecting both the ligand level and the receptor sensitivity simultaneously.

On the short arm of chromosome 9, an intronic variant in TTC39B¹¹ TTC39B
Tetratricopeptide Repeat Domain-Containing Protein 39B — a cytoplasmic scaffold protein that controls the degradation rate of liver X receptors has emerged as one of only a handful of robustly confirmed genetic risk factors for endometriosis. The rs519664 T allele increases endometriosis risk by approximately 29% and carries an even stronger association with severe, surgically confirmed stage III/IV disease. That a gene best known for regulating HDL cholesterol metabolism is linked to a gynaecological condition characterised by chronic peritoneal inflammation points to an underappreciated role of lipid-mediated immune signalling in the development and persistence of endometriotic lesions.

The Mechanism

TTC39B acts as an E3 ubiquitin ligase adaptor that targets liver X receptors (LXRα and LXRβ)²² liver X receptors (LXRα and LXRβ)
nuclear receptors activated by oxysterols — oxidised cholesterol derivatives — that control genes for reverse cholesterol transport, fatty acid synthesis, and inflammation for proteasomal degradation. When TTC39B is functional, LXR protein is continually degraded; when TTC39B activity is reduced, LXR accumulates and drives stronger expression of its target genes — including ABCA1 (intestinal HDL biogenesis) and a suite of anti-inflammatory and cholesterol-efflux genes.

How does this connect to endometriosis? LXR is a known anti-inflammatory transcription factor that suppresses NF-κB signalling and reduces prostaglandin production in macrophages and stromal cells. The peritoneal fluid of women with endometriosis is a highly pro-inflammatory environment rich in activated macrophages, elevated prostaglandin E2 (PGE2), and altered lipid mediator profiles. A TTC39B variant that modulates LXR protein stability would alter the balance between pro-inflammatory and pro-resolution lipid signalling in precisely those peritoneal macrophages that are thought to facilitate endometriotic lesion survival, vascularisation, and immune evasion. The intronic rs519664 variant does not itself change the TTC39B protein, but a nearby region has been identified as a putative regulatory element with physical interactions with the TTC39B promoter — suggesting the T allele alters TTC39B expression rather than function.

The Evidence

The endometriosis association was discovered by Steinthorsdottir et al. 2016³³ Steinthorsdottir et al. 2016
Common variants upstream of KDR encoding VEGFR2 and in TTC39B associate with endometriosis. Nat Commun. 2016 through a whole-genome-sequencing-based GWAS in Iceland (1,840 cases, 129,016 control women), with replication in a Danish cohort. The combined odds ratio for rs519664[T] was 1.29 (p=4.8×10⁻¹⁰). The association was stronger for histologically confirmed stage III/IV disease (OR 1.35, p=1.9×10⁻⁵) than for minimal/mild stage I/II disease (OR 1.21, p=0.013), suggesting the variant particularly predisposes to severe, deeply invasive endometriosis.

The TTC39B locus was subsequently replicated in the large-scale meta-analysis by Sapkota et al. 2017⁴⁴ Sapkota et al. 2017
Meta-analysis identifies five novel loci associated with endometriosis highlighting key genes involved in hormone metabolism. Nat Commun. 2017 (17,045 cases, 191,596 controls), which confirmed 19 independent endometriosis SNPs together explaining ~5% of disease variance. The biological mechanism underpinning the TTC39B locus was established by Tarling et al. 2016⁵⁵ Tarling et al. 2016
TTC39B deficiency stabilizes LXR reducing both atherosclerosis and steatohepatitis. Nature. 2016, which showed that TTC39B is an obligate co-factor for LXR ubiquitination: mice deficient in TTC39B had markedly elevated HDL-C and reduced atherosclerosis, all attributable to LXR protein stabilisation. The most recent large-scale endometriosis GWAS by Rahmioglu et al. 2023⁶⁶ Rahmioglu et al. 2023
The genetic basis of endometriosis and comorbidity with other pain and inflammatory conditions. Nat Genet. 2023 (60,674 cases, 701,926 controls) identified 42 genome-wide significant loci, including the 9p22 region, with effect sizes largest for stage 3/4 ovarian endometriosis.

The T allele is the minor allele in most populations: approximately 22% frequency in Europeans and South Asians, 14% in East Asians, and notably 75% in Africans — a marked frequency reversal that is important context for ancestry-specific risk counselling.

Practical Actions

The T allele raises endometriosis susceptibility at a population level — it is not deterministic. Among women who develop endometriosis, however, T carriers are more likely to progress to the severe stages that cause pelvic adhesions, ovarian endometriomas, and fertility impairment. Early gynaecological evaluation and prompt investigation of cyclical pelvic pain are therefore the most actionable implications of this genotype, since stage III/IV endometriosis diagnosed early can often be managed with less invasive intervention than disease allowed to progress for years.

The LXR-lipid connection also has a practical implication: peritoneal macrophage inflammatory tone and prostaglandin-driven pain are known targets of omega-3 fatty acid supplementation (EPA/DHA), which promotes pro-resolution lipid mediator production. While no endometriosis trial has stratified results by TTC39B genotype, omega-3 supplementation has a plausible mechanistic rationale for T carriers through the same LXR-mediated inflammatory pathway.

Interactions

rs519664 maps to a separate chromosomal region from the other robustly confirmed endometriosis loci, including rs17773813 (upstream of KDR/VEGFR2 on chromosome 4q12, discovered in the same Steinthorsdottir 2016 paper), rs2206949 (ESR1, the oestrogen receptor alpha locus), and multiple GWAS-identified loci involved in sex steroid hormone metabolism. No direct gene-gene interaction between TTC39B and other endometriosis loci has been studied in published datasets, but the combination of a TTC39B T allele (peritoneal inflammatory burden) with oestrogen-signalling loci (ESR1, FSHB) is biologically plausible given that oestrogen upregulates prostaglandin synthesis in endometriotic stroma — the same pathway TTC39B-LXR axis may modulate.

The TNFAIP3 gene on chromosome 6q23 encodes A20, the immune system's primary brake on NF-κB inflammatory signaling¹¹ A20, the immune system's primary brake on NF-κB inflammatory signaling
A20 is a dual-function ubiquitin-editing enzyme — it removes activating K63-linked ubiquitin chains from signaling proteins (deubiquitinase activity) and attaches inhibitory K48-linked chains (E3 ligase activity), together terminating NF-κB activation after an immune response has served its purpose. Multiple independent genetic signals cluster within and around this gene, each perturbing A20-mediated NF-κB suppression through a different mechanism. rs582757 is an intronic variant in intron 5 of TNFAIP3 that has been independently identified as the strongest signal at this locus in psoriasis GWAS — distinct from the upstream intergenic variants (rs6920220, rs10499194/rs13207033) that dominate the RA and SLE literature. Its C allele is the psoriasis risk allele at a population frequency of approximately 28% in European populations, making heterozygous CT carriers a common and clinically relevant group.

The Mechanism

rs582757 resides in intron 5 of TNFAIP3, placing it within the gene body in a regulatory context distinct from the intergenic signals upstream. Like other intronic GWAS hits, it likely acts as a proxy for one or more causal variants within the same linkage disequilibrium block²² linkage disequilibrium block
A chromosomal region where alleles tend to be inherited together; rs582757 tags a haplotype in LD within the TNFAIP3 gene body whose causal functional element has not been fully resolved. Possible functional mechanisms include effects on intronic regulatory elements, enhancer sequences, or pre-mRNA splicing efficiency — any of which could reduce the amount or activity of A20 produced in immune-relevant cell types such as epidermal keratinocytes and dermal dendritic cells.

The downstream consequence is impaired A20-mediated termination of NF-κB signaling in skin. A20 expression is decreased in psoriatic lesional skin compared to non-lesional areas³³ expression is decreased in psoriatic lesional skin compared to non-lesional areas
Sohn et al. 2016 — A20 significantly inhibited poly(I:C)-induced cytokine production in keratinocytes, and its downregulation in psoriatic skin heightens keratinocyte sensitivity to external triggers that drive plaque formation, and this genetic variant's association with psoriasis is consistent with A20 acting as a gatekeeper of keratinocyte NF-κB activation. When A20 activity is reduced, inflammatory cytokines including TNF-α, IL-17, and IL-23 drive the hyperproliferative keratinocyte response that defines psoriatic plaques.

The psoriasis risk haplotype tagged by rs582757-C is genetically distinct from the haplotypes driving RA and SLE risk⁴⁴ genetically distinct from the haplotypes driving RA and SLE risk
The Nititham 2015 meta-analysis explicitly demonstrated that the psoriasis risk haplotype at the TNFAIP3 locus does not overlap with haplotypes reported for other autoimmune diseases, suggesting disease-specific regulatory architecture within the same chromosomal region. This genetic specificity parallels the clinical biology: A20's anti-inflammatory role in skin keratinocytes is a tissue-specific function that differs mechanistically from its role in B-cell tolerance and synovial fibroblast biology.

The Evidence

The strongest evidence for rs582757 comes from a meta-analysis of five European-ancestry psoriasis cohorts⁵⁵ meta-analysis of five European-ancestry psoriasis cohorts
4,704 psoriasis cases and 7,805 controls; Nititham et al. Genes Immun 2015 — five independent replication datasets all showed consistent direction of effect with the C allele totaling 4,704 cases and 7,805 controls. rs582757 emerged as the top TNFAIP3-region signal for psoriasis (P=6.07×10⁻¹², OR=1.23). Conditional analysis on rs582757 revealed a secondary independent signal at rs6918329 (OR=1.15, P=7.22×10⁻⁵), indicating at least two independent genetic effects within the TNFAIP3 region for psoriasis — a pattern consistent with the multi-signal architecture seen for RA at this locus.

For rheumatoid arthritis, fine-mapping of the 6q23 locus in 1,651 Spanish RA patients and 1,619 controls⁶⁶ fine-mapping of the 6q23 locus in 1,651 Spanish RA patients and 1,619 controls
Dieguez-Gonzalez et al. Arthritis Res Ther 2009 — weak evidence for rs582757 association as part of the TNFAIP3 haplotype structure; effect direction and precise magnitude not fully reported in the abstract found rs582757 in the context of a broader TNFAIP3 haplotype associated with RA susceptibility, though the evidence for this variant's independent RA effect is weaker than for psoriasis.

In a Chinese Han population study of rheumatic heart disease⁷⁷ rheumatic heart disease
RHD is an acquired autoimmune condition where streptococcal infection triggers immune responses that damage heart valves, mechanistically involving NF-κB-driven inflammation similar to psoriasis and RA (239 cases, 478 controls), rs582757 showed a striking allele-frequency difference: the C allele was protective with OR 0.57 per allele (95% CI 0.42–0.78, P=0.0004). This means TT homozygotes were at substantially higher RHD risk in this population, illustrating that the risk directionality of rs582757 is disease-specific and population-dependent.

The mechanistic evidence connecting TNFAIP3 to psoriasis pathology is reinforced by expression data: A20 is downregulated in psoriatic lesional skin⁸⁸ downregulated in psoriatic lesional skin
Sohn et al. 2016 — A20 mRNA and protein reduced in plaques vs peri-lesional skin; restoring A20 inhibited poly(I:C)-induced keratinocyte cytokine production and its overexpression in keratinocytes attenuates the cytokine production that drives plaque formation, placing TNFAIP3 function directly in the disease mechanism, not merely associated with it statistically.

The actionable intervention evidence comes from the VITAL randomized controlled trial⁹⁹ VITAL randomized controlled trial
5-year RCT, 25,871 adults, vitamin D3 2,000 IU/day or omega-3 1 g/day vs placebo; Costenbader et al. BMJ 2022 — incident autoimmune disease as primary endpoint, confirmed by medical record review which found vitamin D3 supplementation reduced new autoimmune disease by 22% (HR 0.78, P=0.05) and omega-3 by 15%, both acting on the NF-κB pathway that TNFAIP3/A20 regulates.

Practical Actions

The C allele at rs582757 primarily increases psoriasis susceptibility. For CT and CC carriers, the practical implications center on two areas: skin-directed NF-κB modulation and monitoring for early psoriasis onset. Anti-TNF biologics (adalimumab, etanercept, infliximab) are standard second-line treatments for moderate-to-severe psoriasis and directly target the TNF-α cytokine that A20 normally controls — making TNFAIP3 genotype data relevant to treatment response assessment. Vitamin D, which suppresses NF-κB through nuclear VDR signaling, has both an VITAL-supported systemic autoimmune benefit and topical efficacy as a psoriasis treatment.

Interactions

rs582757 operates within a complex multi-signal TNFAIP3 locus. The psoriasis-specific haplotype it tags is structurally distinct from the RA/SLE-associated haplotypes defined by rs6920220, rs10499194/rs13207033, and rs5029937. A secondary independent psoriasis signal at rs6918329 was identified in the same meta-analysis, suggesting at least two independent regulatory effects within the TNFAIP3 region for psoriasis specifically.

The TNFAIP3 missense variant rs2230926 (F127C) impairs A20 enzymatic activity through a completely different mechanism — reducing the catalytic function of the A20 protein rather than altering its expression or splicing. Carriers of both rs582757 C allele (potentially reduced A20 expression) and rs2230926 G allele (reduced A20 enzymatic function) may face compounded impairment of A20-mediated NF-κB suppression.

TNIP1 (TNFAIP3-interacting protein 1) variants interact functionally with TNFAIP3 — TNIP1 stabilizes A20 protein and directs its substrate specificity. GWAS studies of psoriasis and other autoimmune diseases consistently find both TNFAIP3 and TNIP1 locus signals, suggesting a functional gene-gene interaction worth capturing in compound action analysis.

Von Willebrand factor is the body's primary molecular glue at sites of vascular injury. Synthesized by endothelial cells and platelets, VWF¹¹ VWF
von Willebrand factor — a large glycoprotein that bridges damaged blood vessel walls and circulating platelets to form an initial platelet plug normally circulates as giant multimeric strings. The largest of these high-molecular-weight (HMW) multimers are the most adhesive: they are best at capturing platelets under the shear stress of fast-flowing blood. rs61750584 (G allele) introduces a single amino acid change — isoleucine to threonine at position 1628 (I1628T) — that makes the VWF protein physically fragile at exactly the point where it needs to be strong. The result is von Willebrand disease type 2A, the most common type 2 bleeding disorder, characterized by loss of HMW multimers and a lifelong tendency toward mucocutaneous bleeding.

The Mechanism

The VWF protein contains a central A2 domain²² A2 domain
a compact globular domain flanked by disulfide bonds that conceals the ADAMTS13 cleavage site under physiological conditions. Normally, this domain unfolds only when VWF experiences tensile forces at sites of vascular injury — exposing the Tyr1605–Met1606 bond to proteolysis by ADAMTS13³³ ADAMTS13
a metalloprotease that trims excessively large VWF multimers and prevents pathological platelet clumping. The I1628T substitution sits in a hydrophobic core of the A2 domain. The threonine residue is more polar and bulkier than the native isoleucine, disrupting the network of contacts that hold the domain folded.

Molecular dynamics simulations⁴⁴ Molecular dynamics simulations
computational models applying tensile force to the protein chain and measuring domain stability show that I1628T lowers the tensile force needed to separate the terminal helix α6 from the A2 domain body — the first step in unfolding. Experimental studies confirm that this destabilization translates directly to enhanced ADAMTS13 cleavage: Hassenpflug et al.⁵⁵ Hassenpflug et al.
Impact of mutations in the von Willebrand factor A2 domain on ADAMTS13-dependent proteolysis. Blood 2006;107:2339-45 showed that I1628T increases susceptibility to ADAMTS13 proteolysis under non-denaturing (physiological) conditions, with the in vitro proteolytic pattern closely paralleling the multimer defect seen in affected patients. The consequence is that HMW VWF multimers are cleaved away continuously in the circulation, leaving only small, less-adhesive forms.

The Evidence

ClinVar classifies this variant as Pathogenic for von Willebrand disease type 2A with a 4-star expert panel review (ClinGen VWD Variant Curation Expert Panel, FDA-recognized, last evaluated August 2024). The evidence package meeting this classification includes: at least 16 documented patients with VWD type 2A carrying this variant, segregation with disease across three generations in the original kindred, laboratory confirmation of very low VWF ristocetin cofactor activity and absent HMW multimers in affected carriers, and consistent computational predictions (REVEL score 0.703).

The variant is absent from gnomAD across all major ancestry groups (fewer than 2 alleles observed in 1.4 million chromosomes), consistent with a highly penetrant pathogenic variant under purifying selection pressure. Unlike the common VWD type 1 variants, which typically reduce VWF quantity without structural abnormality, the I1628T mutation causes a qualitative defect: the protein is produced normally but lacks functional HMW multimers.

A landmark functional study by Hassenpflug et al. (2006)⁶⁶ A landmark functional study by Hassenpflug et al. (2006)
examining 13 A2 domain mutations and their ADAMTS13 susceptibility established that nearly all type 2A mutations in the A2 region share this property of enhanced proteolysis, and that the degree of proteolysis in the laboratory predicts the clinical bleeding phenotype. A subsequent structural dynamics study by Interlandi et al. (2012)⁷⁷ structural dynamics study by Interlandi et al. (2012)
PLoS One simulation study of I1628T, L1657I and E1638K confirmed the molecular basis: the threonine substitution reduces the energy barrier for A2 unfolding and is sufficient to render the normally cryptic cleavage site constitutively accessible.

Practical Actions

Carriers of the G allele have pathogenic type 2A VWD inherited in an autosomal dominant pattern — one copy is sufficient to cause disease. Clinical management focuses on three areas: diagnosing the subtype correctly, preparing for bleeding challenges (surgery, trauma, dental procedures), and monitoring for heavy menstrual bleeding.

Laboratory testing should include VWF antigen level, VWF ristocetin cofactor activity (VWF:RCo), VWF:RCo/VWF:Ag ratio (typically less than 0.6 in type 2A), and multimer analysis to confirm the HMW multimer defect. Because type 2A is caused by structural abnormality rather than quantity deficiency, desmopressin (DDAVP)⁸⁸ desmopressin (DDAVP)
which releases VWF from endothelial storage sites but cannot correct the structural defect is generally ineffective or only transiently helpful in type 2A disease. VWF concentrate replacement therapy (plasma-derived or recombinant VWF) is the preferred treatment during bleeding episodes and peri-operative cover.

Interactions

The mucocutaneous bleeding phenotype of VWD type 2A can be compounded by concurrent use of platelet-function inhibitors (aspirin, NSAIDs, clopidogrel), which impair the platelet side of haemostasis that VWF already bridges less effectively. Any prescription involving antiplatelet or anticoagulant drugs requires explicit discussion with a haematologist aware of the VWD diagnosis.

Inherited thrombocytopenia variants (affecting platelet number) could theoretically worsen the bleeding phenotype additively, though published compound heterozygosity data for this specific combination are limited. Factor VIII levels should be checked at baseline, as VWF normally stabilizes FVIII in the circulation; in type 2A, FVIII may be modestly reduced.

The endothelin system is one of the most potent regulators of vascular tone in the human body. Endothelin-1 (ET-1) acts through two receptor subtypes — EDNRA (type A) and EDNRB (type B) — to orchestrate vasoconstriction, vascular smooth muscle proliferation, and arterial wall remodeling. EDNRA is the dominant receptor in vascular smooth muscle and mediates the sustained vasoconstrictive response that maintains cerebrovascular tone¹¹ mediates the sustained vasoconstrictive response that maintains cerebrovascular tone
EDNRA activates Gq-protein signaling, driving IP3-mediated calcium release and PKC activation in smooth muscle cells, producing contraction that can last minutes to hours. rs6841581 sits approximately 900 bp upstream of the EDNRA coding sequence in a region that controls how much receptor protein the cell produces — and one allele makes substantially less of it.

The Mechanism

rs6841581 is a regulatory variant, not a protein-coding change. It lies in the promoter or 5' regulatory region of EDNRA on chromosome 4q31.22 and alters the binding affinity of nuclear transcription factors. Low et al. (2012, Hum Mol Genet) demonstrated that the two alleles of rs6841581 have measurably different affinities for a nuclear protein, and that the susceptible allele drives significantly lower transcriptional activity in luciferase reporter assays²² Low et al. (2012, Hum Mol Genet) demonstrated that the two alleles of rs6841581 have measurably different affinities for a nuclear protein, and that the susceptible allele drives significantly lower transcriptional activity in luciferase reporter assays
Low SK et al. "Genome-wide association study for intracranial aneurysm in the Japanese population identifies three candidate susceptible loci and a functional genetic variant at EDNRA." Human Molecular Genetics, 2012. The result is that carriers of the A allele produce less EDNRA protein per cell.

With fewer functional EDNRA receptors on vascular smooth muscle, the vasoconstrictive response to endothelin-1 is blunted. In cerebral arteries, this impairs the normal maintenance of wall tension and hemodynamic resistance. A heterozygous EDNRA deletion rat model confirmed that reduced EDNRA function is sufficient to trigger intracranial aneurysm formation when combined with hypertensive stress³³ A heterozygous EDNRA deletion rat model confirmed that reduced EDNRA function is sufficient to trigger intracranial aneurysm formation when combined with hypertensive stress
Lampmann et al. 2022 (Brain Sci); EDNRA mutant rats showed more extensive aneurysm formation than wild-type controls under equivalent hypertensive conditions. This animal model provides direct causal evidence that the GWAS signal at rs6841581 reflects true EDNRA dysfunction rather than an indirect association.

The Evidence

The original discovery GWAS by Yasuno et al. (2011, PNAS), combining Japanese discovery cohorts with European replication, linked rs6841581 to intracranial aneurysm risk across 5,891 cases and 14,181 controls⁴⁴ The original discovery GWAS by Yasuno et al. (2011, PNAS), combining Japanese discovery cohorts with European replication, linked rs6841581 to intracranial aneurysm risk across 5,891 cases and 14,181 controls
Yasuno K et al. "Common variant near the endothelin receptor type A (EDNRA) gene is associated with intracranial aneurysm risk." Proc Natl Acad Sci USA, 2011. The association reached genome-wide significance (OR 1.22, P = 2.2 × 10⁻⁸) and held in both East Asian and European populations, making it one of the first trans-ethnic GWAS findings in cerebrovascular genetics.

A meta-analysis of more than 116,000 individuals across 61 studies confirmed rs6841581 as among the most robust genetic risk factors for sporadic intracranial aneurysm (OR 1.22, 95% CI 1.14–1.31)⁵⁵ A meta-analysis of more than 116,000 individuals across 61 studies confirmed rs6841581 as among the most robust genetic risk factors for sporadic intracranial aneurysm (OR 1.22, 95% CI 1.14–1.31)
Alg VS et al. Neurology, 2013. The consistency of effect across diverse populations and study designs places this association in the strong evidence tier for genetic risk research.

An updated East Asian meta-analysis encompassing 20,609 individuals across 6 populations (Hong et al. 2019, World Neurosurg) refined the estimate to OR 1.244 (95% CI 1.174–1.318, P = 1.36 × 10⁻¹³)⁶⁶ An updated East Asian meta-analysis encompassing 20,609 individuals across 6 populations (Hong et al. 2019, World Neurosurg) refined the estimate to OR 1.244 (95% CI 1.174–1.318, P = 1.36 × 10⁻¹³)
Hong EP et al. "Association of Endothelin Receptor Type A with Intracranial Aneurysm in 20,609 East Asians.". The A allele frequency is nearly twice as high in East Asian populations (~28%) compared to Europeans (~14%), meaning the absolute genetic attributable risk is greater in East Asian individuals.

Genome-wide pairwise interaction analyses in a Korean cohort identified 11 SNPs showing genome-wide significant interactions with rs6841581, including variants in RYK (a Wnt co-receptor implicated in vascular development) and TNIK (a MAP3K involved in cytoskeletal regulation)⁷⁷ Genome-wide pairwise interaction analyses in a Korean cohort identified 11 SNPs showing genome-wide significant interactions with rs6841581, including variants in RYK (a Wnt co-receptor implicated in vascular development) and TNIK (a MAP3K involved in cytoskeletal regulation)
Hong EP et al. J Korean Neurosurg Soc, 2023. This interaction architecture suggests that rs6841581's effect on IA risk is amplified by co-occurring variants in vascular developmental pathways.

Practical Actions

Carriers of one or two A alleles at rs6841581 face an incrementally elevated lifetime risk of intracranial aneurysm (unruptured or ruptured as subarachnoid hemorrhage). The per-allele OR of ~1.22–1.24 is modest in absolute terms — population prevalence of unruptured intracranial aneurysms is roughly 2–5% — but the risk is amplifiable by modifiable factors including uncontrolled hypertension and smoking, both of which are potent independent risk factors for aneurysm formation and rupture.

Blood pressure management is the most evidence-supported modifiable lever. The EDNRA pathway mediates ET-1-driven vasoconstriction; reduced EDNRA signaling already impairs vascular wall tension maintenance, and superimposed hypertension exacerbates the hemodynamic stress that triggers aneurysm development. Smoking independently upregulates ET-1 production and promotes vascular inflammation, creating a compounding pro-aneurysm environment for A allele carriers.

MRI angiography (MRA) without contrast can detect unruptured intracranial aneurysms ≥3 mm with high sensitivity and involves no radiation. For A allele carriers with additional risk factors (family history of IA or subarachnoid hemorrhage, hypertension, or smoking history), discussing screening MRA with a neurologist or vascular neurosurgeon is a proportionate response to the genetic finding.

Interactions

rs5335, a 3'UTR variant in the same EDNRA gene, also alters EDNRA expression and is associated with blood pressure variation. Carrying risk alleles at both rs6841581 and rs5335 would be expected to compound the EDNRA downregulation phenotype. The two variants are located at opposite ends of the EDNRA gene (rs6841581 upstream regulatory vs. rs5335 3'UTR) and likely act through independent regulatory mechanisms.

rs6842241, a nearby intergenic variant in the same GWAS locus (Low et al. 2012, OR 1.25), may tag the same functional haplotype as rs6841581 or represent a second independent signal at the EDNRA locus. Both are captured when sequencing this chromosomal region.

rs767603 (LOC105378189) is another intracranial aneurysm susceptibility locus in the heart_inflammation category — the two variants act through independent mechanisms (EDNRA downregulation vs. putative non-coding RNA regulation of vascular wall integrity genes). Both A allele carriers at rs6841581 and T allele carriers at rs767603 benefit from the same blood pressure and smoking avoidance actions.

Alpha-1 antitrypsin (AAT), encoded by SERPINA1, is the body's most abundant serine protease inhibitor and serves as the primary natural inhibitor of Proteinase 3 (PR3)¹¹ primary natural inhibitor of Proteinase 3 (PR3)
PR3 is a neutrophil-derived serine protease that is the main antigenic target of PR3-ANCA antibodies in granulomatosis with polyangiitis (GPA). When AAT function is compromised, unbound PR3 accumulates on neutrophil surfaces and in the circulation, driving autoantibody formation and vascular inflammation. The rs7151526 variant lies approximately 6.7 kilobases downstream of the SERPINA1 coding sequence, in a non-coding regulatory region near the gene's 3' flank. Though not itself a coding change, it has been identified as a risk factor for ANCA-associated vasculitis (AAV)²² ANCA-associated vasculitis (AAV)
AAV encompasses granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA), and eosinophilic GPA — a group of rare but serious autoimmune conditions affecting small blood vessels, with the A allele significantly overrepresented among GPA patients.

The Mechanism

SERPINA1 encodes AAT, whose primary job is to neutralize PR3 released by activated neutrophils during inflammatory episodes. When PR3 is left uninhibited — whether due to reduced AAT levels or impaired AAT function — it can trigger an autoimmune cascade: unbound PR3 on neutrophil surfaces becomes an exposed antigen, stimulating production of anti-PR3 ANCA antibodies. These antibodies then activate more neutrophils in a self-amplifying loop, causing necrotizing inflammation of small vessels — the hallmark of AAV.

The rs7151526 variant is located in a non-coding region (primarily affecting lncRNA transcripts) with "MODIFIER" impact by VEP annotation. Its exact molecular mechanism of action is not fully characterized; however, regulatory variants in the 3' flanking region of genes can affect mRNA stability, expression level, or splicing of nearby transcripts. Research shows that even in patients with normal AAT protein concentrations, AAT functional activity is dramatically lower in Wegener's granulomatosis³³ normal AAT protein concentrations, AAT functional activity is dramatically lower in Wegener's granulomatosis
Mota et al. found TIC and specific AAT activity significantly decreased despite equivalent protein levels (p=0.001), suggesting that subtle changes in AAT expression or function — potentially mediated by non-coding regulatory variants like rs7151526 — can tip the protease-antiprotease balance toward disease.

The Evidence

A meta-analysis of 18 eligible studies⁴⁴ meta-analysis of 18 eligible studies
Banerjee et al., International Journal of Rheumatic Diseases, 2022 confirmed rs7151526-A as a significant predisposing allele for GPA (Meta-OR = 2.70, 95% CI 1.51–4.85, p = 0.0008). This finding was consistent across studies and confirms that carrying the A allele approximately doubles to triples the odds of developing GPA compared to CC homozygotes.

The clinical stakes are considerable. A 2024 prospective cohort study of 115 Brazilian AAV patients⁵⁵ 2024 prospective cohort study of 115 Brazilian AAV patients
Giardini et al., Clinics (São Paulo), 2024 — predominantly GPA (65.2%) — found SERPINA1 polymorphisms to be "the most significant factor linked to mortality" in multivariate analysis (HR = 6.2, 95% CI 1.4–27.1, p = 0.015). Carriers of rs7151526 had a mean survival of 57.4 years, compared to 68.0 years in non-carriers — a reduction of more than a decade. A French retrospective cohort of 142 AAV patients⁶⁶ French retrospective cohort of 142 AAV patients
Deshayes et al., Journal of Rheumatology, 2019 found that patients with deficient AAT alleles had significantly higher rates of intraalveolar hemorrhage (p < 0.01), a severe and potentially fatal pulmonary complication.

Population frequencies confirm this is a predominantly European variant: the A allele occurs at ~4.8% in Europeans, versus ~0.1% in East Asians and ~0.9% in Africans. The overall global minor allele frequency is approximately 3.4% (gnomAD v4). Given the additive genetic architecture and the rarity of AAV itself (~3 per 100,000 per year), the absolute risk increase is modest, but the prognostic impact once disease develops appears substantial.

Practical Actions

Carrying the A allele does not mean you will develop AAV — the condition remains rare even in genetically predisposed individuals, and environmental triggers (infections, silica exposure, drugs) are required. However, awareness of this genetic signal supports a lower threshold for clinical evaluation when relevant symptoms appear. ANCA-associated vasculitis characteristically presents with upper respiratory tract symptoms⁷⁷ upper respiratory tract symptoms
ENT symptoms including chronic sinusitis, nosebleeds, saddle-nose deformity in GPA; subglottic stenosis, lower respiratory disease (cough, hemoptysis), kidney involvement (hematuria, proteinuria, rising creatinine), and systemic features (fatigue, weight loss, fever). Prompt ANCA testing and rheumatology referral at symptom onset significantly improves outcomes.

For those who carry this variant, early disease recognition is the most actionable step. ANCA-associated vasculitis treated in early disease stages — before irreversible organ damage — has substantially better outcomes than disease diagnosed late with severe renal or pulmonary involvement.

Interactions

rs7151526 is distinct from the classical SERPINA1 deficiency alleles (rs28929474, the Z allele E342K, and rs17580, the S allele E264V). The Z allele (rs28929474) is strongly pathogenic for classic AAT deficiency lung and liver disease, and is independently associated with even stronger GPA risk (Meta-OR = 12.60 for the Z allele versus 2.70 for rs7151526 in Banerjee 2022). The related SNP rs28929454 (also studied in the Giardini 2024 mortality cohort) showed even more pronounced survival reduction. Individuals carrying rs7151526-A alongside classical deficiency alleles would likely face compounded risk, though direct interaction data is limited.

The mechanism connects rs7151526 to the broader ANCA vasculitis genetic architecture, which includes variants in CTLA4 (rs231775) and other immune regulatory genes identified in the same meta-analysis. PR3-ANCA positive AAV has distinct genetic risks from MPO-ANCA positive disease, and rs7151526's association appears primarily driven by GPA (PR3-ANCA) cases.

Every day your liver handles a continuous stream of spent red blood cells, converting their released haemoglobin into bilirubin and then rendering that bilirubin water-soluble so it can be excreted in bile. The enzyme that carries out this final conjugation step is UGT1A1¹¹ UGT1A1
UDP-glucuronosyltransferase 1A1, a phase II detoxification enzyme that attaches glucuronic acid to unconjugated bilirubin, making it soluble and excretable, encoded by the UGT1A1 gene on chromosome 2q37. When this enzyme is severely reduced, unconjugated bilirubin — fat-soluble and capable of crossing the blood-brain barrier — accumulates in blood and tissues, causing jaundice and, at extreme levels, neurological damage.

The rs72551348 variant (c.992A>G) causes a glutamine-to-arginine substitution at position 331 of the UGT1A1 protein (p.Gln331Arg, also written Q331R). This missense change disrupts the enzyme's catalytic efficiency for bilirubin conjugation, leaving only a fraction of normal activity. ClinVar classifies it as Pathogenic²² ClinVar classifies it as Pathogenic
RCV000013058, associated with Crigler-Najjar syndrome type II, and it was first described by Moghrabi et al.³³ Moghrabi et al.
Moghrabi N et al. Identification of an A-to-G missense mutation in exon 2 of the UGT1 gene complex that causes Crigler-Najjar syndrome type 2. Genomics, 1993 in a 72-year-old Irish man born of consanguineous parents, whose diagnosis was established when phenobarbital treatment significantly lowered his chronically elevated bilirubin.

The variant affects a shared exon of the UGT1A gene complex, meaning the same nucleotide change disrupts multiple UGT1A isoforms (UGT1A1, UGT1A3–A10 all read from this exon). However, UGT1A1 is the only isoform directly responsible for bilirubin glucuronidation, and Crigler-Najjar syndrome is the primary clinical consequence.

The Mechanism

Gln331 sits in the C-terminal membrane-anchoring domain of UGT1A1, a region important for proper enzyme folding and substrate binding. The arginine substitution introduced by the G allele alters local protein conformation, substantially impairing the enzyme's ability to glucuronidate bilirubin. Unlike type I Crigler-Najjar mutations, which completely abolish UGT1A1 activity, Q331R leaves residual activity — estimated at less than 10% of normal in type II patients — a threshold established by functional expression studies⁴⁴ a threshold established by functional expression studies
Seppen J et al. Discrimination between Crigler-Najjar type I and II by expression of mutant bilirubin uridine diphosphate-glucuronosyltransferase. J Clin Invest, 1994. This residual activity is the mechanistic basis for the key clinical feature of type II disease: phenobarbital responsiveness. Phenobarbital is an inducer of UGT1A1 gene expression; boosting transcription from the residual functional allele can meaningfully increase the amount of conjugated bilirubin produced, lowering serum levels by 30% or more.

The Evidence

Crigler-Najjar syndrome type II is rare — fewer than 300 cases have been documented in the medical literature. The Q331R variant (rs72551348) is ultrarare even among UGT1A1 disease alleles, with a G allele frequency of approximately 3.7 × 10⁻⁵ in the gnomAD exome dataset (predominantly in individuals of European ancestry). No homozygous individuals have been observed in population databases, consistent with the rarity of type II Crigler-Najjar syndrome.

Functional characterisation established⁵⁵ Functional characterisation established
Seppen et al. 1994 that the hallmark of type II mutations is partial enzyme inactivation (residual activity 4–38% across patients), versus zero activity in type I. This residual activity keeps serum bilirubin below 20 mg/dL in most type II patients — well below the levels that cause kernicterus — and explains the far better neurological prognosis compared to type I.

A comprehensive genotype-phenotype review⁶⁶ A comprehensive genotype-phenotype review
Kadakol A et al. Hum Mutat, 2000 cataloguing more than 50 UGT1A1 mutations confirmed that the partial-vs-complete enzyme inactivation distinction maps reliably to type II vs type I phenotype, with the critical threshold being whether any residual bilirubin-conjugating activity remains.

Practical Actions

For homozygous carriers (GG) — clinically the relevant genotype for Crigler-Najjar type II — the management priorities are phenobarbital therapy to upregulate residual UGT1A1 expression, bilirubin monitoring, and awareness of drug interactions. Because UGT1A1 metabolises several chemotherapy agents (particularly irinotecan and belinostat), any cancer treatment plan should account for the severely reduced enzyme activity. UV-A phototherapy can be used adjunctively during bilirubin spikes. Liver transplantation is curative and is typically reserved for cases where phenobarbital cannot maintain safe bilirubin levels or when quality of life is severely impaired.

Heterozygous carriers (AG) — one G allele with one normal A allele — have approximately 50% of normal UGT1A1 activity and are clinically normal. Their primary concern is reproductive: if both partners carry a pathogenic UGT1A1 allele, there is a 25% probability of a homozygous child with Crigler-Najjar syndrome.

Interactions

rs72551348 falls on the same UGT1A1 gene that harbours several other clinically significant variants. Compound heterozygosity with the common UGT1A1*28 promoter variant (rs8175347, extra TA repeat reducing expression by ~70% when homozygous) or with *6 Gly71Arg (rs4148323, prevalent in East Asia) can produce a combined UGT1A1 impairment intermediate between Gilbert syndrome and Crigler-Najjar type II. Any individual carrying one Q331R allele should be tested for other UGT1A1 variants, particularly if bilirubin levels are higher than expected for a simple carrier.

Sex hormone-binding globulin is the liver's primary traffic controller for testosterone and estradiol. Only about 1–3% of testosterone circulates as "free" bioactive hormone — the rest is bound to SHBG (roughly 44%) or albumin (54%). When SHBG levels rise, more testosterone gets locked away; when SHBG levels fall, more free testosterone is available to act on tissues. Rs727428 is one of the best-replicated [genetic regulators | This variant has been identified as genome-wide significant in multiple independent GWAS and validated across ancestries] of circulating SHBG levels, located just outside the SHBG gene itself in a downstream regulatory region.

The Mechanism

Rs727428 sits approximately 1 kb downstream of the SHBG gene on chromosome 17p13.1, in a [regulatory region | This area contains chromatin elements that influence SHBG gene expression in the liver; GERP conservation score and Ensembl RegBuild both annotate it as a functional regulatory feature] outside the protein-coding sequence. The variant does not change the SHBG protein structure — it acts by influencing how much SHBG the liver produces. The T allele at this position is associated with reduced SHBG transcription relative to the C allele. Each copy of the T allele reduces serum SHBG by approximately 3–4 nmol/L [| Grigorova et al. 2017, PMID 29264510 — P=7.3×10⁻¹¹, effect −3.74 nmol/L per allele], meaning TT homozygotes produce measurably less SHBG than CC homozygotes. Because SHBG binds testosterone with roughly five times higher affinity than albumin, small changes in SHBG concentration have outsized effects on how much testosterone is biologically active in tissues.

The Evidence

The original genome-wide significant association between rs727428 and circulating SHBG was established in a GWAS of ~1,600 postmenopausal women¹¹ GWAS of ~1,600 postmenopausal women
Prescott et al. PLoS One, 2012 where the T allele was associated with lower SHBG (β=−0.126 on a log scale, P=2.09×10⁻¹⁶). This finding was simultaneously replicated in a GWAS of 3,225 European men²² GWAS of 3,225 European men
Jin et al. Human Molecular Genetics, 2012, where rs727428 showed genome-wide significant associations with both total testosterone (P=1.26×10⁻¹²) and dihydrotestosterone (DHT, P=1.47×10⁻¹¹).

A validation study in 1,687 Japanese men³³ validation study in 1,687 Japanese men
Sato et al. Human Reproduction Open, 2019 replicated the SHBG association (β=0.21, P=3.4×10⁻¹⁰) but did not replicate testosterone association after multiple testing adjustment, suggesting that in East Asian populations the effect on SHBG may not translate directly into measurable testosterone differences — possibly because other loci or lifestyle factors modulate free testosterone differently in this population.

A population-based sibling study of 999 Dutch men⁴⁴ population-based sibling study of 999 Dutch men
Walravens et al. Journal of Clinical Endocrinology & Metabolism, 2025 found that rs727428 T allele homozygotes had 10.8–23.1% lower SHBG and 3.9–21.4% lower total testosterone compared to CC homozygotes. Notably, calculated and directly measured free testosterone showed minimal difference across genotypes — suggesting the body compensates for SHBG-driven total testosterone changes by adjusting LH/FSH feedback to maintain free testosterone homeostasis in healthy men.

In women, a Mediterranean PCOS case-control study of 1,004 premenopausal women⁵⁵ Mediterranean PCOS case-control study of 1,004 premenopausal women
Martínez-García et al. Human Reproduction, 2012 found the T allele was more frequent in PCOS patients than controls (OR=1.29), independent of obesity. A family-based PCOS study in 758 women⁶⁶ family-based PCOS study in 758 women
Wickham et al. Journal of Clinical Endocrinology & Metabolism, 2011 confirmed that rs727428 genotype was independently associated with SHBG levels after controlling for BMI, insulin resistance, and free testosterone. Meta-analyses have shown mixed results: one 2020 meta-analysis (1,660 cases, 1,312 controls) found the association with PCOS susceptibility was not statistically significant after pooling, while individual studies — particularly in Mediterranean and Middle Eastern populations — consistently found associations. The discrepancy likely reflects population-specific allele frequencies and PCOS diagnostic heterogeneity.

Practical Implications

The clinical consequences of rs727428 depend heavily on context. In women, lower SHBG from the T allele means more free testosterone and a higher [free androgen index | FAI = total testosterone ÷ SHBG × 100; values above 4–5 in women are associated with androgenic symptoms and PCOS]. Women with TT genotype benefit most from monitoring free androgen index rather than total testosterone, and from strategies that support SHBG production — particularly insulin-sensitizing approaches, since insulin is a potent suppressor of hepatic SHBG synthesis. In men, lower SHBG generally keeps more testosterone available in tissue, but the Walravens 2025 data suggest the body's hormonal feedback loop largely compensates in healthy young men. Where this compensation may fail is in older men, men with metabolic syndrome, and men undergoing testosterone monitoring for hypogonadism — in these contexts, SHBG genotype should inform how total testosterone is interpreted.

Interactions

rs1799941 (SHBG promoter G-68A): This variant in the SHBG promoter acts independently from rs727428 to regulate SHBG levels. The A allele of rs1799941 increases SHBG by 15–25%, opposing the T allele effect at rs727428. The Grigorova 2017 study (PMID 29264510) found these variants replicate independently — both are significant GWAS hits with distinct mechanisms (one alters promoter transcription factor binding; the other affects downstream regulatory architecture). A person carrying T at rs727428 AND G at rs1799941 has two additive SHBG-lowering variants; a person carrying T at rs727428 AND A at rs1799941 has opposing forces that may partially cancel. This is a strong candidate for a compound action given the opposite-direction effects in the same pathway.

rs6259 (SHBG Asp327Asn): A missense variant in the SHBG protein (p.Asp327Asn) that reduces testosterone binding affinity by approximately 10%, thereby increasing free testosterone bioavailability even when total SHBG concentration is unaffected. In men, the A allele of rs6259 was associated with increased free testosterone in the Walravens 2025 study. Compound carriers of both the rs727428 T allele (less SHBG protein) and the rs6259 A allele (SHBG protein with lower binding affinity) would have a compounded increase in free testosterone — relevant for interpreting androgen status in both sexes.

Compound action proposal for rs727428 TT + rs1799941 GG: Women carrying TT at rs727428 AND GG at rs1799941 carry two independent SHBG-lowering variants — one reducing transcription rate (promoter), one reducing downstream regulatory expression. The combined recommendation: measure free androgen index (FAI = total testosterone ÷ SHBG × 100); track SHBG as a metabolic risk biomarker; implement insulin-sensitizing strategies (inositol supplementation has evidence for PCOS with low SHBG); and discuss combined SHBG genotype result with clinician before interpreting any sex hormone panel. Evidence level: moderate (individual effects well-established; combined effect inferred from independent pathway data).

The LDL receptor (LDLR) encoded by the LDLR gene is the primary mechanism by which the liver clears low-density lipoprotein (LDL) cholesterol from the bloodstream. Each functional LDLR molecule captures LDL particles at the hepatocyte surface and draws them into the cell via receptor-mediated endocytosis, where cholesterol is released for cellular use. Pathogenic LDLR mutations disrupt this clearance system, allowing LDL cholesterol to accumulate in the blood from birth — the defining feature of familial hypercholesterolemia (FH)¹¹ familial hypercholesterolemia (FH)
autosomal dominant disorder causing severe, lifelong LDL-C elevation and dramatically accelerated atherosclerosis.

rs730882105 is an extremely rare missense variant in LDLR that substitutes methionine for valine at amino acid position 524 (c.1570G>A, p.Val524Met). It has been classified as likely pathogenic by the British Heart Foundation LDLR-LOVD database²² likely pathogenic by the British Heart Foundation LDLR-LOVD database
the LDLR Leiden Open Variation Database maintained by the BHF is the most comprehensive curated registry of LDLR variants with clinical significance assignments, though a second submitter classified it as uncertain significance under stricter ACMG 2015 criteria, and a Merck Research Labs functional study found no significant impairment in vitro. The conflicting evidence reflects a genuine ambiguity in this rare variant: population frequency is too low for robust statistical association, and functional assay results diverge from clinical reports. This YAML entry reflects the intermediate evidence state.

The Mechanism

Val524 sits within the [ligand-binding domain cluster of LDLR | the extracellular ligand-binding domain consists of seven cysteine-rich repeats (LBD1–7) that directly contact apolipoprotein B-100 on LDL particles and apolipoprotein E on VLDL/IDL particles] — specifically in or near repeat 7 (LBD-7), a region required for efficient LDL binding and cellular uptake. Valine-to-methionine substitutions introduce a larger, more polar side chain that can disrupt the local protein conformation, though the magnitude of functional impairment varies by exact position and surrounding structure. The Merck in vitro data suggesting no effect may reflect assay conditions not replicating the full hepatic context of LDL binding and recycling; real-world FH reports in carriers are the stronger signal for a receptor with known genotype-phenotype correlation.

Untreated heterozygous FH (one mutated LDLR copy) typically produces LDL-C of 190–400 mg/dL from birth — levels that accelerate atherosclerotic plaque formation decades earlier than in the general population. Ference et al. 2017³³ Ference et al. 2017
Low-density lipoproteins cause atherosclerotic cardiovascular disease. European Heart Journal established that the cumulative LDL burden from birth (not just current levels) drives atherosclerosis; this is why FH carriers begin accumulating plaques in their teens and 20s and may have their first myocardial infarction before age 50.

The Evidence

rs730882105 is too rare (2 alternate alleles in 1.4 million gnomAD samples) to accumulate direct statistical evidence for this specific variant. Its likely pathogenic classification rests on: (1) location in a functionally critical LDLR domain; (2) clinical reports of FH phenotype in at least one carrier submitted to the LDLR-LOVD; (3) the prior probability that missense variants disrupting LDLR ligand-binding repeats are pathogenic, which is high based on the 3,200+ characterized LDLR variants catalogued by Abifadel & Boileau 2023⁴⁴ Abifadel & Boileau 2023
Genetic and molecular architecture of familial hypercholesterolemia. J Intern Med, where missense variants account for ~60% of all pathogenic LDLR mutations.

The broader FH evidence base is compelling: untreated heFH carries a [substantially elevated risk of CHD | coronary heart disease — up to 13-fold excess risk per the EAS consensus] Defesche et al. 2017⁵⁵ Defesche et al. 2017
Familial hypercholesterolaemia. Nat Rev Dis Primers. The global prevalence of FH is approximately 1:250 (1:80 in founder populations such as French Canadians and Afrikaners) — far higher than previously thought. Most remain undiagnosed. Tokgozoglu & Kayikcioglu 2021⁶⁶ Tokgozoglu & Kayikcioglu 2021
Familial Hypercholesterolemia: Global Burden and Approaches. Curr Cardiol Rep estimated that >85% of FH individuals globally are undetected. With statin therapy achieving ≥50% LDL reduction, the excess cardiovascular risk is substantially attenuated — making early identification and treatment directly life-extending.

Practical Actions

Heterozygous carriers of rs730882105 should have a fasting lipid panel performed to establish baseline LDL-C levels. LDL-C >190 mg/dL in an adult with a likely pathogenic LDLR variant typically meets criteria for high-intensity statin therapy (rosuvastatin 20–40 mg or atorvastatin 40–80 mg). The LDL-C target is <100 mg/dL for those without established cardiovascular disease, and <70 mg/dL for those with prior ASCVD events. If statin therapy alone is insufficient, ezetimibe (adds ~15% LDL reduction) and PCSK9 inhibitors (alirocumab, evolocumab — add ~50% LDL reduction) are guideline-recommended additions. Sturm et al. 2018⁷⁷ Sturm et al. 2018
Clinical Genetic Testing for Familial Hypercholesterolemia: JACC Scientific Expert Panel recommends cascade screening of all first-degree relatives when a pathogenic LDLR variant is identified — each child of a carrier has a 50% chance of inheriting the mutation.

Saturated fat restriction to below 7% of total calories specifically reduces hepatic LDL production and complements statin therapy in FH; this is one of few dietary interventions with FH-specific evidence because it operates through the same LDL-receptor pathway that LDLR mutations impair.

Interactions

LDLR variants interact in severity with PCSK9 gain-of-function variants (rs28942078, rs72658867) and APOB p.Arg3527Gln: carriers of both a pathogenic LDLR variant and a PCSK9 gain-of-function variant have substantially more severe LDL elevation than either alone, as PCSK9 degrades the LDL receptor — compounding the LDLR mutation's reduced receptor availability. Double heterozygotes are estimated to have FH severity approaching homozygous FH. APOE ε4 (rs429358) also modestly elevates LDL-C and is relevant context for cardiovascular risk assessment in carriers.